XML 74 R54.htm IDEA: XBRL DOCUMENT v3.20.4
Major Customers and Concentration of Credit Risk (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Concentration Risk [Line Items]                      
Total revenues $ 5,580,581 $ 236,178 $ 267,187 $ 1,327,274 $ 279,488 $ 866,863 $ 135,673 $ 2,829,905 $ 7,411,220 $ 4,111,930 $ 30,481,897
Revenue | Customer Concentration Risk                      
Concentration Risk [Line Items]                      
Concentration risk, percentage                 100.00% 100.00% 100.00%
ApolloBio                      
Concentration Risk [Line Items]                      
Total revenues                 $ 0 $ 0 $ 23,000,000
ApolloBio | Revenue | Customer Concentration Risk                      
Concentration Risk [Line Items]                      
Concentration risk, percentage                 0.00% 0.00% 75.00%
AstraZeneca                      
Concentration Risk [Line Items]                      
Total revenues                 $ 170,587 $ 3,194,877 $ 6,850,424
AstraZeneca | Customer Concentration Risk                      
Concentration Risk [Line Items]                      
Accounts receivable         161,000         $ 161,000  
AstraZeneca | Revenue | Customer Concentration Risk                      
Concentration Risk [Line Items]                      
Concentration risk, percentage                 2.00% 78.00% 23.00%
AstraZeneca | Accounts Receivable | Customer Concentration Risk                      
Concentration Risk [Line Items]                      
Concentration risk, percentage                   23.00%  
Advaccine                      
Concentration Risk [Line Items]                      
Total revenues                 $ 5,000,000 $ 0 $ 0
Advaccine | Customer Concentration Risk                      
Concentration Risk [Line Items]                      
Accounts receivable 7,100,000               $ 7,100,000    
Advaccine | Revenue | Customer Concentration Risk                      
Concentration Risk [Line Items]                      
Concentration risk, percentage                 68.00% 0.00% 0.00%
Advaccine | Accounts Receivable | Customer Concentration Risk                      
Concentration Risk [Line Items]                      
Concentration risk, percentage                 38.00%    
Plumbline Life Sciences, Inc.                      
Concentration Risk [Line Items]                      
Total revenues                 $ 1,370,396 $ 0 $ 0
Plumbline Life Sciences, Inc. | Revenue | Customer Concentration Risk                      
Concentration Risk [Line Items]                      
Concentration risk, percentage                 18.00% 0.00% 0.00%
All other, including affiliated entities                      
Concentration Risk [Line Items]                      
Total revenues                 $ 870,237 $ 917,053 $ 631,473
All other, including affiliated entities | Revenue | Customer Concentration Risk                      
Concentration Risk [Line Items]                      
Concentration risk, percentage                 12.00% 22.00% 2.00%
DoD | Customer Concentration Risk                      
Concentration Risk [Line Items]                      
Accounts receivable $ 11,400,000               $ 11,400,000    
DoD | Accounts Receivable | Customer Concentration Risk                      
Concentration Risk [Line Items]                      
Concentration risk, percentage                 62.00%    
MCDC | Customer Concentration Risk                      
Concentration Risk [Line Items]                      
Accounts receivable         $ 469,000         $ 469,000  
MCDC | Accounts Receivable | Customer Concentration Risk                      
Concentration Risk [Line Items]                      
Concentration risk, percentage                   67.00%